Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "SKELETAL MUSCLE RYANODINE RECEPTOR" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In skeletal muscle, activation of ryanodine receptors occurs via a physical coupling to the dihydropyridine receptor (a voltage-dependent, L-type calcium channel), whereas, in cardiac muscle, the primary mechanism of activation is calcium-induced calcium release, which causes calcium outflow from the sarcoplasmic reticulum.
Synergistic Mixtures of Anthranilamide Invertebrate Pest Control Agents
Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, and its N-oxides, and suitable salts thereof and a component (b) wherein the component (b) is at least one compound or agent selected from neonicotinoids, cholinesterase inhibitors, sodium channel modulators, chitin synthesis inhibitors, ecdysone agonists, lipid biosynthesis inhibitors, macrocyclic lactones, GABA-regulated chloride channel blockers, juvenile hormone mimics, ryanodine receptor ligands, octopamine receptor ligands, mitochondrial electron transport inhibitors, nereistoxin analogs, pyridalyl, flonicamid, pymetrozine, dieldrin, metaflumizone, biological agents, and suitable salts of the foregoing. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a mixture or composition of the invention.
Owner:FMC CORP
Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
InactiveUS20050215540A1Inhibition of fibrillationBiocideOrganic active ingredientsVentricular dysrhythmiaRyanodine receptor
The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
O-formammidotiazol-benzamide derivatives based on ryanodine receptor, and preparation method and applications thereof
The invention provides o-formammidotiazol-benzamide derivatives, and a preparation method and applications thereof. The o-formammidotiazol-benzamide derivatives have the chemical structure general formula represented by the formula I or the formula II. The invention discloses the structure general formula of the compounds, the synthesis method and the applications of the compounds as insecticides, acaricides and bactericides; the compounds are mixed with agriculturally acceptable auxiliary agents or synergistic agents for use in processing crafts of preparing the insecticides, the acaricides and the bactericides. The invention also discloses the applications of the compounds in combination with the commercial insecticides, the acaricides, the bactericides, anti-plant virus agents and plant activators for prevention and treatment of agriculture, forestry, horticulture plant diseases, insect attacks, acarus attacks and virus diseases, and the preparation method of the compounds.
Owner:JIANGXI TIANREN ECOLOGY
Screening method
InactiveUS20040013609A1Effect is exertedReduce contentSenses disorderMicrobiological testing/measurementEpitheliumErg
The invention relates to a method for identification of substances which are applicable for treatment or prevention of an insufficient longitudinal growth of the eye (hypermetropia) or for treatment or prevention of an excessive longitudinal growth of the eye (myopia); substances identified by the method for treating or preventing conditions related to the longitudinal growth of the eye; substances and mixtures of substances for the preparation of a pharmaceutical composition for the treatment or prevention of abnormal growth of the axial length of the eye. The identification involves measuring the effect of the substances on the retinal pigment epithelium of the eye, e.g. by detecting the metabolic effect of the substance on the retinal epithelium, the effect on the standing potential or the effect on the proteoglycanes of the scleral tissue of the eye, by way of EOG examination, by way on the size of the so-called c-wave in ERG-recordings, or by the state of the Ca<2+>-channels or on the [<3>H]-ryanodine receptors of the retinal pigment epithelium.
Owner:TRIER KLAUS
Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
InactiveUS20050187386A1Improve bindingLimiting and preventing in levelOrganic active ingredientsOrganic chemistryRyanodine receptorMedicine
The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
InactiveUS20060293266A1Effective treatmentBiocideOrganic active ingredientsPhosphodiesteraseRyanodine receptor complex
The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases malignant hyperthermia, diabetes and sudden infant death syndrome. The present invention further provides methods for regulating PKA phosphorylation of a ryanodine receptor as well as methods for regulating Ca+2 release and reuptake in cells. Also provided are kits for use in delivering a PDE-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
O-carboxamido benzamide derivative based on ryanodine receptor, and preparation method and application thereof
The invention provides a series of o-carboxamido benzamide derivatives, and preparation methods and applications thereof. The o-carboxamido benzamide derivatives have the chemical structure general formula represented as the formula I. The invention also discloses: the general formula and the synthetic method of the compounds and an application of the compounds in insecticides, acaricides and bactericides, and a process of preparing the acaricides and bactericides by mixing the compounds with agriculturally acceptable additives or synergists, and also discloses the combination of the compounds with commercial insecticides, acaricides, bactericides, anti-plant-viral agents and plant activators to prevent and treat diseases, pest damage, mite damage and viral diseases in the fields of agriculture, forestry and horticulture.
Owner:JIANGXI TIANREN ECOLOGY
Agents for treating disorders involving modulation of ryanodine receptors
ActiveUS20140088171A1Excellent propertyHigh metabolic stabilityOrganic active ingredientsBiocideDiseaseRyanodine receptor
The present invention relates to 1,4-benzothiazepine derivatives and their use to treat conditions, disorders and diseases associated with ryanodine receptors (RyRs) that regulate calcium channel functioning in cells. The invention also discloses pharmaceutical compositions comprising the compounds and uses thereof to treat diseases and conditions associated with RyRs, in particular cardiac, musculoskeletal and central nervous system (CNS) disorders.
Owner:ARMGO PHARMA
Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
InactiveUS7393652B2Microbiological testing/measurementDisease diagnosisChemical compoundRyanodine receptor
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Type 1 ryanodine receptor-based methods
InactiveUS7312044B2Avoid dissociationReduce dissociationCompounds screening/testingOrganic active ingredientsRyanodine receptorSkeletal muscle
This invention provides methods of treating defective skeletal muscle function during heart failure and methods for identifying compounds useful in such treatments.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Pesticide composition for shortening the virus lethal time
The present invention is related to a pesticide composition for shortening the virus lethal time that comprises 0.01-75% of a ryanodine receptor insecticide or a diamides insecticide and 107-1012 PIB / ml of baculovirus. The pesticide composition of the present invention can effectively reduce the lethal time to the pest compared to the baculovirus alone, and also can increase the control effect of the pest compared to the same concentration of the insecticide.
Owner:NAT TAIWAN UNIV
Transgenic animal model for catecholaminergic polymorphic ventricular tachycardia (CPVT) and use thereof
The present invention refers to non-human transgenic mammals, preferably rodents, or mice, which comprise a mutation in the gene encoding for the cardiac ryanodine receptor (RyR2).Transgenic animals carrying the amino acid change R4496C in the RyR2 protein show a phenotype similar to that of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) (OMIM: 604772). Further provided are methods for using these animals as in vivo model of Catecholaminergic Polymorphic Ventricular Tachycardia and RyR2 dependent arrhythmias, in drug screening and for understanding the molecular basis of RyR2 dependent arrhythmias.
Owner:PRIORI SILVIA G +1
Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2) and uses thereof
InactiveCN1980677AOrganic active ingredientsCardiovascular disorderVentricular dysrhythmiaRyanodine receptor
The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Method of modulating activity of calcium channels in cardiac cells and reagents therefor
The present invention relates generally to novel peptides that are capable of modulating the activity of calcium channels in cardiac cells. More specifically, the present invention provides a method of modulating the activity of a cardiac calcium channel comprising contacting a cardiac ryanodine receptor (RyR2) with an amount of a fragment of a dihydropyridine receptor (DHPR) polypeptide sufficient to modulate the activity of said RyR2, and determining the activity of said calcium channel. The inventive method is useful for the treatment of a range of disorders and diseases associated with cardiac dysfunction, particularly those diseases and disorders involving reduced cardiac output and / or aberrant excitation-contraction coupling, calcium overload, or calcium leakage, in cardiac cells.
Owner:AUSTRALIEN NAT UNIV
Methods of determining activity of ryanodine receptor modulators
InactiveUS20070196856A1Different absorptionDifferent emissionBiocideImage analysisSKELETAL MUSCLE RYANODINE RECEPTORCell biology
Methods for identifying modulators of ryanodine receptors are disclosed. In preferred embodiments the activity of the ryanodine receptor is stimulated to a baseline level and the ability of a test compound to increase or decrease the baseline level indicates that the test compound is a modulator of ryanodine receptor activity.
Owner:ALLERGAN INC
Ryanodine receptor blockers for treating pain
InactiveUS20070066638A1Relieve painSufficient quantityBiocideNervous disorderDantrolenePreventing pain
The present invention provides a method of preventing or ameliorating pain in a mammal comprising administering to said mammal suffering from or at risk of suffering a noxious action causing said pain, an effective amount of a ryanodine antagonist, such as dantrolene, to inhibit or prevent pain.
Owner:ALLERGAN INC
Pharmacological therapy for neuronopathic Gaucher disease
The instant disclosure relates to methods and compositions for the treatment of Gaucher disease, particularly type II and III neuronopathic Gaucher disease (nGD). The methods include the step of administering to an individual in need thereof an effective amount of a ryanodine receptor inhibitor or a pharmaceutically acceptable salt thereof.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI
Method and special primer of method for fast identifying plutella xylostella ryanodine receptor gene mutation
InactiveCN102952889ATimely adjustment of prevention and control strategiesHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationAgricultural scienceOpen reading frame
The invention discloses a method and a special primer of the method for fast identifying the plutella xylostella ryanodine receptor gene mutation. The invention provides a specific primer combination, which consists of a single chain DNA (deoxyribonucleic acid) molecule shown as a sequence 1 of a sequence table, a single chain DNA molecule shown as a sequence 2 of the sequence table and a single-chain DNA molecule shown as a sequence 3 of the sequence table. The specific primer combination can be used for the following (a) or (b): (a) the specific primer combination can be used for identifying whether plutella xylostella generates the G4899E mutation of the ryanodine receptor gene or not, and the G4899E mutation of the ryanodine receptor gene refers to that an open reading frame of the ryanodine receptor gene is mutated into A from G in the 14696 locus nucleotide of the 5' tail end; and (b) the specific primer combination is used for the auxiliary identification of the resistance of plutella xylostella on bisamide pesticides. The specific primer combination and the application of the specific primer combination have the important significance in the aspects of monitoring the resistance gene frequency of plutella xylostella field populations on the bisamide pesticides and the bisamide pesticide resistance generation and development trend of the plutella xylostella field populations, timely regulating the plutella xylostella preventing and control strategy, guiding the reasonable pesticide use and delaying the resistance development.
Owner:CHINA AGRI UNIV
Chilo suppressalis ryanodine receptor gene CsRyR, encoded protein thereof and application of chilo suppressalis ryanodine receptor gene CsRyR
InactiveCN102628049AFungiCell receptors/surface-antigens/surface-determinantsNucleotideRyanodine receptor
The invention discloses a chilo suppressalis ryanodine receptor gene CsRyR, which is used for encoding a nucleotide sequence with a chilo suppressalis ryanodine receptor protein CsRyR, wherein the nucleotide sequence has at least 70 percent of homology with a nucleotide sequence shown as SEQ ID NO:1. The invention further discloses a protein encoded by using the chilo suppressalis ryanodine receptor gene CsRyR. The protein has an amino acid sequence shown as SEQ ID No:2. The chilo suppressalis ryanodine receptor gene CsRyR is used for screening and / or evaluating a substance for regulating and controlling the activity of a chilo suppressalis ryanodine receptor.
Owner:ZHEJIANG UNIV
Agents for preventing and treating disorders involving modulation of the ryanodine receptors
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Composition with ZJ10520 and ryanodine receptor insecticide
ActiveCN107616176AMeet security requirementsAchieve bactericidalBiocideFungicidesSKELETAL MUSCLE RYANODINE RECEPTORMedication cost
The invention discloses a bactericidal and insecticidal composition with ZJ10520 and ryanodine receptor insecticide. The bactericidal and insecticidal composition has the advantages that good bactericidal and insecticidal effects can be realized by the bactericidal and insecticidal composition, the bactericidal and insecticidal composition is low in medication frequency and medication cost, and the safety requirements on pesticide preparations can be met.
Owner:ZHEJIANG RES INST OF CHEM IND CO LTD +2
Pharmaceutical composition comprising a ryanodine receptor antagonist for facilitating wound healing
ActiveUS20160303085A1Increase blood flowIncrease the diameterOrganic active ingredientsPharmaceutical delivery mechanismDiseaseEpithelium
The invention relates to the use of pharmaceutical compositions containing as the active agent a compound of formula I in the treatment of dermal wounds. The compositions may be used for the promotion of healing of wounds affecting the deeper layers under the epithelium, including dermal- and sub dermal connective tissue, being cut, punctured, sliced wounds or originating in insufficient tissue perfusion, chronic diseases or other harms. The compositions are formulated for local application and may comprise other active agents contributing to wound healing in addition to a compound of formula (I).
Owner:SZEGEDI TUDOMANYEGYETEM
Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
InactiveUS7718644B2Inhibition of fibrillationOrganic active ingredientsBiocideBenzothiazepine derivativesMedicine
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Fluorescent probe for screening drugs acting on ryanodine receptor
ActiveCN111808058AOrganic chemistryFluorescence/phosphorescenceRyanodine receptorPharmaceutical drug
The invention discloses a fluorescent probe for screening drugs acting on a ryanodine receptor. The structural formula of the probe is shown as a formula (I) which is described in the specification. The fluorescent probe for screening the drug acting on the ryanodine receptor can directly and specifically bind to a ryanodine receptor existing in a cell system of an insect, and can be replaced by other drugs binding to the ryanodine receptor of the insect, so the fluorescent probe can be used for screening drugs interacting with the ryanodine receptor of the insect.
Owner:TIANJIN UNIV
Molecular detection method and special primer for resistance of sesamia inferens to chlorantraniliprole
ActiveCN105734154AHigh sensitivityTimely adjustment of prevention and control strategiesMicrobiological testing/measurementOpen reading frameAgricultural science
The invention discloses a molecular detection method and special primer for resistance of sesamia inferens to chlorantraniliprole, and provides a special primer composition which is composed of single-chain DNA molecules shown in the sequence 1, the sequence 2 and the sequence 3 in the sequence table. The special primer composition can be used for detecting whether gene G4924E mutation happens to an acting site, namely, a ryanodine receptor, of chlorantraniliprole or not. The gene G4924E mutation of the ryanodine receptor of sesamia inferens means that the 14771th nucleotide at the 5' end of an open reading frame of the ryanodine receptor gene mutates into A from G, and therefore resistance of sesamia inferens to chlorantraniliprole is detected. The special primer composition and application of the special primer composition have important significance in monitoring development trends of resistance of sesamia inferens field populations to chlorantraniliprole, guiding reasonable pesticide utilization, delaying resistance development, formulating resistance government policies and regulating prevention and control strategies in time.
Owner:ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES
Molecular detection method for resistance of chilo suppressalis to chlorantraniliprole and primers special for method
InactiveCN105755144AHigh sensitivityTimely adjustment of prevention and control strategiesMicrobiological testing/measurementAgricultural scienceOpen reading frame
The invention discloses a molecular detection method for resistance of chilo suppressalis to chlorantraniliprole and primers special for the method.The invention provides a specific primer composition which is composed of single-chain DNA molecules as shown in a sequence 1, a sequence 2 and a sequence 3 in a sequence table.The specific primer composition can be used for detecting whether an action site ryanodine receptor of chlorantraniliprole is subjected to gene G4946E mutation or not, G4946E mutation of a ryanodine receptor gene of chilo suppressalis means that the 14837 nucleotide located at the 5' tail end of an open reading frame of the ryanodine receptor gene is mutated into A from G, and therefore the resistance of chilo suppressalis to chlorantraniliprole is detected.The specific primer composition and application thereof have important significance in monitoring a development trend of the resistance of chilo suppressalis field populations to chlorantraniliprole, guiding reasonable pesticide use, delaying resistance development, making a resistance management policy and adjusting a control strategy in time.
Owner:ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES
Electrochemical luminescence kit for detecting RyR-Ab and preparation method thereof
PendingCN111007261AThe detection process is fastHigh sensitivityChemiluminescene/bioluminescenceBiological testingAntigenAntiendomysial antibodies
The invention relates to a novel electrochemical luminescence kit for detecting an anti-Ryanodine receptor antibody (RyR) from a blood sample and a preparation method thereof. The prepared kit comprises a streptavidin-coated magnetic bead particle working solution, a biotin-labeled RyR antigen working solution, a terpyridyl-ruthenium-labeled anti-human IgG antibody working solution, a RyR-Ab calibration material and / or quality control material working solution, a tripropylamine-containing electrochemiluminescence substrate solution and a cleaning solution. A luminescence system of the preparedkit is electrochemiluminescence, a streptavidin-biotin biological reaction signal amplification system is utilized, the detection speed is high, the sensitivity is high, the linear range is wide, thedetection result repeatability is good; and accurate quantitative detection of RyR-Ab in blood can be realized.
Owner:江苏三联生物工程股份有限公司
Method and special primer of method for fast identifying plutella xylostella ryanodine receptor gene mutation
InactiveCN102952889BTimely adjustment of prevention and control strategiesHigh sensitivityMicrobiological testing/measurementDNA/RNA fragmentationBiotechnologyOpen reading frame
Owner:CHINA AGRI UNIV
Ntranasal dantrolene administration for treatment of alzheimer's disease
PendingUS20220354827A1Reduce releaseImproving and slowing declineOrganic active ingredientsNervous disorderRyanodine receptorSynaptogenesis
Methods for inhibiting impaired neurogenesis and / or synaptogenesis in neurons in a subject with or suspected of having Alzheimer's Disease (AD), methods for improving and / or slowing the decline of cognitive function after onset of neuropathology and cognitive dysfunction, which neuropathology and cognitive dysfunction are caused by AD, methods for improving and / or slowing the decline of memory before onset of symptoms of AD, methods for increasing concentration and duration of dantrolene in the brain, and methods for improving and / or slowing the decline of memory after onset of symptoms of AD, the methods comprising intranasally administering to a subject in need thereof an amount of a pharmaceutical composition comprising dantrolene effective to inhibit over-activation of N-methyl-D-aspartate (NMVDA) receptor and / or ryanodine receptor (RyR). Methods further comprise administering a therapeutically effective amount of a glutamate receptor antagonist to the subject.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
A composition containing zj10520 and ryanodine receptor insecticides
ActiveCN107616176BMeet safety requirementsReduce the number of medicationsBiocideFungicidesRyanodine receptorSKELETAL MUSCLE RYANODINE RECEPTOR
Owner:ZHEJIANG RES INST OF CHEM IND CO LTD +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com